Rodman & Renshaw Global Healthcare Conference 2008 Presenter Profiles
2008-05-16 10:02:54 -
www.businesswire.com - Rodman & Renshaw Global Healthcare Conference 2008 takes place May 19-20, 2008 at the Le Meridien Beach Plaza Hotel, in Monte Carlo, Monaco. In-depth information about the event is available at www.rodmanandrenshaw.com/conferences?id=18&link=confinfo.
Business Wire is the official news wire for the Rodman & Renshaw Global Healthcare Conference. Listed below are profiles from the conference presenters. Breaking news releases and photos are available at www.tradeshownews.com, Business Wire's trade show, conference, and event news resource. -0- Company: Access Pharmaceuticals, Inc. Ticker Symbol & Exchange: ACCP.OB Investor Relations Contact: Stephen B. Thompson Investor Relations Contact Phone: 214-905-5100 Web: www.accesspharma.com Date of Presentation: Monday, May 19, 2008 Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, MuGard(TM) for the management of oral mucositis. The company's lead oncology product is ProLindac(TM), a polymer-linked platinum cancer drug, which is in Phase 2 clinical testing in recurrent ovarian cancer patients. Angiolix(R), an antiangiogenic humanized monoclonal antibody, and Prodrax(R), a hypoxia-activated prodrug, are the company's lead preclinical oncology products. Access is also developing oral insulin and oral hGH using its proprietary Cobalamin(TM) oral drug delivery technology. Company: Active Biotech AB Ticker Symbol & Exchange: ACTI OMX Nordic Investor Relations Contact: Goran Forsberg Investor Relations Contact Phone: 46 46 19 11 54 Web: www.activebiotech.com Date of Presentation: 20-May Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(R) for RA. Company: Addex Pharma SA Ticker Symbol & Exchange: ADXN Investor Relations Contact: Chris Maggos Investor Relations Contact Phone: 41 22 884 15 11 Web: www.addexpharma.com Date of Presentation: 20/05/2008 Addex Pharmaceuticals Ltd discovers and develops allosteric modulators, an emerging class of small molecule therapeutic agents. Allosteric modulation may offer more sophisticated ways to normalize biological signaling compared to classical orthosteric agonist or antagonist drugs. Lead product, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), showed clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) and migraine. The company has 12 early stage products. The Addex allosteric modulation discovery and development platform has been additionally validated through product collaborations with Merck & Co., Inc. and Johnson & Johnson. Company: Biosante Pharmaceuticals, Inc. Ticker Symbol & Exchange: BPAX/NASDAQ Investor Relations Contact: Phillip Donenberg Investor Relations Contact Phone: 847-478-0500 ext 100 Web: www.biosantepharma.com Date of Presentation: 19-May-08 BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to- severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Company: Cyclacel Pharmaceuticals, Inc. Ticker Symbol & Exchange: CYCC Investor Relations Contact: Corey Sohmer Investor Relations Contact Phone: 1 908 517 7330 Web: www.cyclacel.com Date of Presentation: May 20th Cyclacel is a diversified biopharmaceutical business dedicated to the discovery, development and commercialization of novel, targeted drugs to treat cancer. Cyclacel's strategy is focused on leading edge therapeutic management of cancer patients based on a portfolio of three medicines marketed by its ALIGN subsidiary and a deep development pipeline. Three orally-available drugs are in clinical development: sapacitabine (in two randomized Phase 2 studies for the treatment of elderly acute myeloid leukemia and cutaneous T-cell lymphoma); seliciclib (in two randomized Phase 2 studies for the treatment of lung and nasopharyngeal cancers) and CYC116 (in Phase 1 in patients with solid tumors). Company: Cytori Therapeutics Ticker Symbol & Exchange: CYTX Investor Relations Contact: Tom Baker Investor Relations Contact Phone: 858.458.0900 Web: www.cytoritx.com Date of Presentation: 5.19.08 Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(TM) 900 System will be launched in Asia-Pacific for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com Company: DOV Pharmaceutical, Inc. Ticker Symbol & Exchange: DOVP.OB Investor Relations Contact: Barbara Duncan Investor Relations Contact Phone: 732-907-3604 Web: www.dovpharm.com Date of Presentation: 19-May-08 DOV is a biopharmaceutical company focused on the development of novel product candidates for disorders of the central nervous system, or CNS. We currently have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21, 947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. Company: Evotec AG Ticker Symbol & Exchange: FSE:EVT, NASDAQ:EVTC Investor Relations Contact: Anne Hennecke Investor Relations Contact Phone: 49-40-56081-286 Web: www.evotec.com Date of Presentation: May 20, 2008, 11.00 am CET Evotec is a leader in the discovery and development of novel small molecule drugs. In proprietary projects, Evotec specializes in finding new treatments for diseases of the CNS. Evotec has 3 programs in clinical development: EVT201, a partial positive allosteric modulator of the GABA-A receptor complex for the treatment of insomnia, EVT101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT302, a MAO-B inhibitor in development for smoking cessation. Evotec's proprietary preclinical research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Evotec has worldwide collaboration and license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists. Company: FIBREX MEDICAL Inc. Investor Relations Contact: Rainer Henning, President & CE Investor Relations Contact Phone: 43-1-86634-9270 Web: www.fibrexmedical.com Date of Presentation: 20-May FIBREX MEDICAL is a development stage biopharmaceutical company with operations in Vienna/Austria. The company mission is to develop and commercialize innovative therapeutics in the fields of cardiovascular diseases and inflammation. FIBREX MEDICAL is discovering and developing peptides and peptide analogs with anti-inflammatory and endothelial protectant activity. Lead compound FX06MRI is under clinical evaluation for the treatment of reperfusion injury after myocardial infarction via a novel mechanism of action. Company: Genetic Imunity Investor Relations Contact: Dr. Julianna Lisziewicz ; Dr. Zsolt Lisziewicz Investor Relations Contact Phone: 36-302-116402 Web: www.geneticimmunity.com Date of Presentation: May 19: from 09:20 to 09:40 AM Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company focused on the discovery, development and commercialization of topically administered Nanomedicines for targeted immune amplification. The Company's Nanomedicine platform focuses on significant unmet medical needs such as infectious diseases, cancer and allergies. The DermaVir Patch, Genetic Immunity's lead Nanomedicine candidate, is in Phase II clinical development and could be the first Nanomedicine approved for HIV/AIDS. Phase I/II trials to date of the DermaVir Patch have confirmed safety and tolerability and the amplification of HIV-specific T cell precursors (PHPC), which correlate with decreased viral load (Caralota et al, J Immunol 2008). Company: GTC Biotherapeutics Ticker Symbol & Exchange: GTCB NASDAQ Investor Relations Contact: Thomas Newberry Investor Relations Contact Phone: 508-370-5374 Web: www.gtc-bio.com Date of Presentation: 20-May-08 GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn(R), GTC's recombinant form of human antithrombin, is approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes at a competitive cost. Additional information is at www.gtc-bio.com. Company: Haemacure Ticker Symbol & Exchange: HAE: TSX Investor Relations Contact: Joseph Galli - 1.514.990.7074 Investor Relations Contact Phone: Diane Roch - 514.282.3350 x27 Web: www.haemacure.com Date of Presentation: May 20 at 1:40p.m. - Zephir Room Haemacure is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next- generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Additional information available on www.haemacure.com. Company: Helsinn Healthcare SA Investor Relations Contact: Alessandro Bossi Investor Relations Contact Phone: 41 (0) 91 9852121 41 (0) 79 5084705 Web: www.helsinn.com Date of Presentation: May 19, 2008 12:30pm (10:30am GMT) Helsinn Healthcare SA announced today that Mr.Riccardo Braglia, CEO, will present an overview of the company, its products and corporate goals at the Rodman & Renshaw Global Healthcare Conference, Monte Carlo, Monaco on May 19th 2008 at 12:30pm (10:30am GMT). The presentation will be webcast live and can be accessed by logging on to the web site (www.wsw.com/webcast/rrshq13/helsinn). An archived version is available for 90 days. Helsinn (www.helsinn.com) is a privately owned Swiss-based pharmaceutical group. Core business: pain, inflammation, oncology and supportive care. Business strategy: in-license early stage new chemical entities, complete their development up to market approvals and out-license to its worldwide network of partners. The active pharmaceutical ingredients and drug products are manufactured at Helsinn's cGMP facilities. Company: Hythiam, Inc. Ticker Symbol & Exchange: HYTM: NASDAQ Investor Relations Contact: Lisa Wilson Investor Relations Contact Phone: In-Site Communications, Inc., 212- 759-3929 Web: www.hythiam.com Date of Presentation: Monday, May 19, 2008 at 5:15 pm Hythiam, Inc. provides behavioral health management services to health plans, employers, criminal justice, and government agencies through a network of licensed and company managed healthcare providers. Hythiam approaches the management of behavioral health disorders with a focus on using the latest medical and health technology aimed towards improved outcomes and out-patient treatment. Hythiam offers disease management for substance dependence built around its patented PROMETA Treatment Program for alcoholism and dependence to stimulants. Hythiam also researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Company: Inovio Biomedical Ticker Symbol & Exchange: INO Investor Relations Contact: Bernie Hertel Investor Relations Contact Phone: 858 410-3101 Web: www.inovio.com Date of Presentation: 19-May-08 Inovio Biomedical (AMEX: INO) is focused on developing multiple DNA- based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation, using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Human data has shown that Inovio's electroporation-based DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. Company: Interleukin Genetics, Inc. Ticker Symbol & Exchange: AMEX: ILI Investor Relations Contact: Melanie Friedman Investor Relations Contact Phone: 212-362-1200 Web: www.ilgenetics.com Date of Presentation: 19-May-08 Interleukin Genetics is a science-based personalized health company using applied genetics to empower consumers to improve their health. Interleukin is studying the role of inflammatory genes in diseases of aging and has commercialized the PST(R) Periodontal genetic test, the Gensona(R) IL-1 Cardiovascular genetic test and the Gensona(R) General Nutrition genetic test. In addition to launching its own tests, Interleukin aims to partner with biotechnology and pharmaceutical companies to develop molecular diagnostics. Interleukin is also developing genetic tests to address health risks for osteoporosis, obesity, arthritis and cancer and sells an array of Nutraceuticals through some of the nation's largest retailers. Company: Lev Pharmaceuticals, Inc. Ticker Symbol & Exchange: LEVP Investor Relations Contact: Jason Tuthill Investor Relations Contact Phone: 212-850-9130 Web: www.levpharma.com Date of Presentation: 5/20/2008 Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor), is being developed as a replacement therapy for both the acute and prophylactic treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze(TM) has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Company: Maxygen Ticker Symbol & Exchange: Nasdaq: MAXY Investor Relations Contact: Michele Boudreau Investor Relations Contact Phone: 650-297-2088 Web: www.maxygen.com Date of Presentation: 19-May-08 Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. Company: Neotropix, Inc. Investor Relations Contact: Peter Lanciano, CEO; Planciano@neotropix.com Investor Relations Contact Phone: 617-460-1200 Web: www.neotropix.com Date of Presentation: 20-May-08 Neotropix develops several cancer drugs using a proprietary and innovative platform sourcing natural products that selectively bind to cancer cells and naturally kill through lysis. The lead product NTX-010 is a highly selective drug that specifically treats carcinoid, small cell and several pediatric neuroendocrine cancers. NTX-010 is currently completing enrollment in a large carcinoid trial. Data demonstrates the ability of NTX-010 to obtain significant clinical effect as compared to the control group in each of time-to-progression, reduction in tumors and key biochemical markers. The clincal study is being conducted at multiple USA centers including John Hopkins, USO, Mt Sinai and Mary Crowley Cancer Research Center. Company: Novelos Therapeutics, Inc. Ticker Symbol & Exchange: OTCBB: NVLT Investor Relations Contact: Stephen Lichaw Investor Relations Contact Phone: 201-240-3200 Web: www.novelos.com Date of Presentation: May 19, 2008, 2:30pm Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. Company: Osteologix, Inc. Ticker Symbol & Exchange: OLGX.OB Investor Relations Contact: Baxter Phillips, III Investor Relations Contact Phone: 804.754.6970 Web: www.osteologix.com Date of Presentation: Monday, May 19 Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. It is our vision to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. We partner with the healthcare community to apply new scientific information and clinical data to the development of products that improve patient care in a safe and ethical manner. Osteologix's lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. Company: Pluristem Therapeutics Inc. Ticker Symbol & Exchange: NASDAQ:PSTI; DAX:PJT Investor Relations Contact: William Prather RPh, MD Investor Relations Contact Phone: 1-303-883-4954 Web: www.pluristem.com Date of Presentation: 20 May 2008 at 9:00 a.m. Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products targeting Peripheral Artery Disease (PAD), as well as Bone Marrow Transplantation (BMT), ischemic stroke, Multiple Sclerosis and additional autoimmune disorders, such as Crohn's disease. The Company's product candidates are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source and are stored ready-to-use. The placental cells are expanded in the Company's proprietary PluriX(TM) 3D bioreactor and are termed PLX (PLacental eXpanded) cells. Pluristem's products have the potential to participate in the approximate $30B therapeutic and regenerative cellular market. Company: Synvista Therapeutics Ticker Symbol & Exchange: AMEX: SYI Investor Relations Contact: Kim Golodetz, LHA Investor Relations Contact Phone: 212-838-3777 Date of Presentation: 19-May-08 Synvista Therapeutics is a biopharmaceutical company developing drugs and diagnostics for cardiovascular disease and nephropathy in diabetics. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase, one of which is in Phase 2, which metabolizes lipid peroxides and has the potential to limit myocardial damage subsequent to myocardial infarction. It is also developing alagebrium, a breaker of AGEs, currently in Phase 2 for treatment of heart failure. The Company is also developing several clinical diagnostic tests, among them one for cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes. Company: TopoTarget A/S Ticker Symbol & Exchange: OMX: TOPO Investor Relations Contact: Rachel Curtis Gravesen, Investor Relations Contact Phone: 45 25 12 62 60 Web: www.topotarget.com Date of Presentation: 20-May-08 TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer." Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. We have top class experts in clinical development, regulatory and pre- clinical departments. TopoTarget's lead product belinostat is due to begin a pivotal trial in the second half of 2008 and we have a further 8 products in clinical development. Using our own highly specialised dedicated sales team, we launched our first marketed product, Savene(R)/Totect(R) in Europe/US in 2006 and 2007 respectively. Savene(R)/Totect(R) is used for the treatment of anthracycline extravasation, an accident that can occur during chemotherapy. Company: Transdel Pharmaceuticals, Inc. Ticker Symbol & Exchange: OTCBB: TDLP Investor Relations Contact: John Lomoro, CFO; johnl@transdelpharma.com Investor Relations Contact Phone: 858-457-5300 Web: www.transdelpharma.com Date of Presentation: May 19, 2008, 4:35 pm local time Specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known localized anti- inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.
Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow (at) businesswire.com.
Business Wire
Global Event Services, 310-820-9473
